Trials / Completed
CompletedNCT04213469
PD1-CD19-CART in Patients With r/r B-cell Lymphoma
a Safety and Efficacy Evaluation of PD1-CD19-CART in Patients With Relapse/Refractory B-cell Lymphoma
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Bioray Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-site, dose-escalation study in up to 25 participants with relapse/refractory B-NHL. This study aims to evaluate the safety and efficacy of the treatment with PD1-CD19-CART.
Detailed description
PD1-CD19-CART is a kind of chimeric antigen T cell targeting CD19 with both CD19-CAR gene integration and also PD1 knockout by one-step gene-editing. After completion of study treatment, subject participation for this study will be followed up to 15 years post T cell infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells | Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1 |
Timeline
- Start date
- 2020-03-13
- Primary completion
- 2021-11-01
- Completion
- 2023-11-10
- First posted
- 2019-12-30
- Last updated
- 2024-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04213469. Inclusion in this directory is not an endorsement.